Loading...
XHKG
6127
Market cap4.34bUSD
Jul 10, Last price  
20.32HKD
1D
11.46%
1Q
-9.61%
IPO
-59.59%
Name

Joinn Laboratories China Co Ltd

Chart & Performance

D1W1MN
XHKG:6127 chart
P/E
44.26
P/S
7.95
EPS
0.40
Div Yield, %
0.18%
Shrs. gr., 5y
3.61%
Rev. gr., 5y
9.03%
Revenues
1.66b
-17.87%
97,389,156143,828,848184,814,905206,605,666241,805,209301,278,957408,798,150639,379,3381,075,904,9341,516,680,0312,267,970,9792,376,486,7972,018,333,7711,657,624,302
Net income
298m
+302.08%
9,625,52822,288,28548,996,19649,173,91351,692,49376,446,395108,338,318178,372,735315,013,896557,459,6091,074,257,178396,992,56574,075,384297,841,047
CFO
445m
+31.17%
20,331,87760,907,38082,375,992106,225,419118,822,186120,006,161176,075,671148,092,126428,385,736685,655,427971,066,113622,875,138338,928,718444,566,722
Dividend
Jun 26, 20250.032799 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of preclinical and non-clinical services to clients across the United States, China, and other international regions. The company's business is organized into three core operational areas. Its Non-Clinical Studies Services segment focuses on drug safety assessment, drug metabolism and pharmacokinetics analysis, and pharmacology and efficacy investigations. The Clinical Trial and Related Services division offers contract research organization (CRO) support for clinical trials, co-manages Phase I clinical research units, and provides bioanalytical services. Furthermore, the Sales of Research Models segment is involved in the design, production, breeding, and distribution of various research models, including non-human primates and rodents. Beyond these offerings, Joinn Laboratories also provides investment management and cell-based assay (CBA) services. Founded in 1995, the company is headquartered in Beijing, China.
IPO date
Aug 25, 2017
Employees
2,500
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT